Efficiency of ipratropium bromide and salbutamol deposition in the lung delivered via a soft-spray inhaler or chlorofluorocarbon metered-dose inhaler Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Improved delivery of fenoterol plus ipratropium bromide using Respimat(R) compared with a conventional metered dose inhaler Source: Eur Respir J 2001; 17: 225-232 Year: 2001
Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) inhaled from a new soft mist inhaler (SMI) and from a conventional metered dose inhaler (MDI) in asthma patients Source: Eur Respir J 2001; 18: Suppl. 33, 70s Year: 2001
In vitro comparison of aerosol characteristics of HFA ipratropium bromide pressurized metered dose inhaler (pMDI) formulation from three valved holding chambers (VHCs) Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I Year: 2011
Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) delivered by a new soft mist inhaler (SMI) or a conventional metered dose inhaler (MDI) in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 70s Year: 2001
Comparison of the safety relating to paradoxical bronchoconstriction of ipratropium bromide (IB) alone or combined with fenoterol hydrobromide (FEN) inhaled from a new soft mist inhaler (SMI) and from a conventional metered dose inhaler (CFC-MDI) in Source: Eur Respir J 2002; 20: Suppl. 38, 246s Year: 2002
Ipratropium bromide HFA propellant inhaler has equivalent safety and efficacy to the marketed CFC propellant inhaler in bronchial asthma Source: Eur Respir J 2001; 18: Suppl. 33, 70s Year: 2001
Comparison of the long-term efficacy and safety of ipratropium bromide (IB) delivered by a new soft mist inhaler (SMI) versus conventional metered dose inhaler (MDI) in COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 69s Year: 2001
Similar delivery of ipratropium bromide is possible at approximately one-half dose via a breath-actuated nebulizer compared with a continuous nebulizer Source: Eur Respir J 2005; 26: Suppl. 49, 306s Year: 2005
Effect of patient age on response to nebulised salbutamol or ipratropium bromide Source: Annual Congress 2012 - Going with the flow: assessment and evaluation of airway function and its role in patient management Year: 2012
In vivo pulmonary deposition of aclidinium bromide from a multidose dry powder inhaler Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008
Delivered dose and fine particle dose of aclidinium bromide 200 µg via the Genuair® inhaler are independent of flow rate within the working range of the device Source: Annual Congress 2010 - Drug delivery and pharmacokinetics I Year: 2010
Comparison of systemic pharmacodynamic effects of two HFA formulations of formoterol fumarate delivered by pressurised metered dose inhaler in healthy subjects Source: Annual Congress 2009 - New aspects of inhalation therapy Year: 2009
In vitro comparison of aerosol characteristics of HFA albuterol (salbutamol) pressurized metered dose inhaler (pMDI) formulation from three valved holding chambers (VHCs) Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II Year: 2011
Comparison of proficiency of pressurized metered dose inhaler (pMDI) use with asthma control Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008
Physicochemical compatibility of ipratropium, albuterol and fluticasone nebulizer solutions Source: Eur Respir J 2006; 28: Suppl. 50, 211s Year: 2006
Comparison of a dry powder inhaler (DPI) to a pressurized metered-dose inhaler (pMDI) formulation of extra fine beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB) in patients with COPD: The TRI-D study. Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils Year: 2020
Evaluation of bronchodilator response to single dose tiotropium bromide Source: Eur Respir J 2004; 24: Suppl. 48, 504s Year: 2004
Changes in the lung metabolic functions by inhalation of ipratropium bromide Source: International Congress 2019 – Exploring the lungs in various pathophysiological conditions Year: 2019
Efficacy of ipratropium bromide/ fenoterol hydrobromide HFA and CFC propellant inhalers in patients with COPD Source: Eur Respir J 2003; 22: Suppl. 45, 52s Year: 2003